MAVS and neoplasm: The anti-tumour mechanism of RIG-I agonists is mainly activated by the MAVS/Type I IFN signalling pathway in tumour cells or innate immune cells (Elion et al, 2018; Heidegger et al, 2019a; Heidegger et al, 2019b).